Pre-Treatment and Post-Treatment I-131 Imaging in Differentiated Thyroid Carcinoma
Journal of Clinical Medicine · 29.03.2024 · 13 (7) · 1984
DOI: 10.3390/jcm13071984 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.03.2024. Verfasst von Jasna Mihailović. Beteiligte Einrichtung: Department of Nuclear Medicine, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Republic of Serbia, Autonomous Province of Vojvodina, Provincial Secretariat for High Education and Scientific Research.
Abstract (Originalsprache)
Radioiodine imaging in initial perioperative settings, after the total thyroidectomy, includes pre-treatment and post-treatment radioiodine imaging. While the benefit of post-treatment whole-body imaging (PT-WBI) is well established, the role of diagnostic whole-body imaging (dx WBI), prior to radioiodine (I-131) ablative or therapeutic doses, is controversial. Dx WBI has been abandoned in most nuclear medicine centers long ago. Planar low-dose dxWBI provides the volume of postoperative thyroid remnants, but it cannot detect occult metastatic foci in the neck. The modern integrated multimodality, i.e., SPECT/CT imaging, provides three dimensional images and accurate anatomic/metabolic data. This hybrid technology offers better spatial resolution but not better sensitivity. Dx WBI has low theranostic power because of the radioiodine indifference and low detection sensitivity for small-volume nodal disease in the neck. Since dx WBI cannot clarify the paratracheal cervical uptake, thyroid remnants may be easily misinterpreted as nodal disease, leading to a false N upstaging (from N0 stage to N1 stage) in DTC patients. Post-ablation I-131 imaging has a significant role in the initial staging of radioiodine-avid DTC and in the identification of non-radioiodine avid tumors. Additionally, SPECT/CT in the post-treatment setting provides more accurate initial TNM staging and better risk stratification of DTC patients. Post-treatment I-131 imaging is obligatory and must be performed in all DTC patients who receive radioiodine treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.
- Division of Nuclear Medicine, Oncology Institute of Vojvodine, Put dr Goldmana 4, 21204 Sremska Kamenica, Serbia.
ORCID-Profile: Jasna Mihailović
Förderung
- Republic of Serbia, Autonomous Province of Vojvodina, Provincial Secretariat for High Education and Scientific Research
Zitieren
APA
Mihailović, J. (2024). Pre-Treatment and Post-Treatment I-131 Imaging in Differentiated Thyroid Carcinoma. Journal of Clinical Medicine, 13(7), 1984. https://doi.org/10.3390/jcm13071984
Vancouver
Mihailović J. Pre-Treatment and Post-Treatment I-131 Imaging in Differentiated Thyroid Carcinoma. Journal of Clinical Medicine. 2024;13(7):1984. doi:10.3390/jcm13071984
BibTeX
@article{Mihailovi2024,
author = {Mihailović, Jasna},
title = {Pre-Treatment and Post-Treatment I-131 Imaging in Differentiated Thyroid Carcinoma},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {7},
pages = {1984},
doi = {10.3390/jcm13071984}
}
EUVIMED